Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Trevena oliceridine patent us?

See the DrugPatentWatch profile for oliceridine

Does oliceridine (Trevena) have an active patent in the US?

Trevena’s oliceridine is covered by multiple patent families in the United States, but the exact status of “the” patent depends on which specific patent number, claim set, and expiry or patent-term-adjustment are involved. Public information on a single, definitive “US oliceridine patent expiry date” is usually not enough because different patents on different aspects (for example, composition, methods of use, or related technologies) can expire at different times.

When would Trevena’s oliceridine patents expire in the US?

Patent expiry in the US depends on the filing date and any adjustments (like patent term adjustment), plus whether there are terminal disclaimers or other adjustments. Without a specific patent identifier (number or application), it’s not possible to state a single reliable expiry date.

What parts of oliceridine’s intellectual property are most likely driving exclusivity?

For drugs like oliceridine, US protection often comes from:
- Composition-of-matter patents (covering the molecule)
- Method-of-use patents (covering specific dosing or clinical use)
- Process or formulation-related patents (manufacturing or formulation)
Each can have a different expiry window, so “patent expiration” for one patent may not mean generic entry is immediate.

Could generics or “similar” products enter before all patents expire?

Yes. In practice, a generic or follow-on product may launch once it can address or wait out the specific patents that block its path. Even if one patent expires, other listed patents can keep exclusivity in place. Launch timing also depends on the regulatory pathway and any litigation stay or settlements tied to that pathway.

Are there other US exclusivity protections besides patents?

Even after patents expire, other legal exclusivities (such as marketing exclusivity tied to regulatory milestones) can affect timing. Those are separate from patent term and can extend the period in which a competitor cannot market a same/near-same product.

What do you need to check to get the exact “US patent” answer for oliceridine?

To determine the exact US patent status and expiry, you typically need one of the following:
- A specific US patent number for the oliceridine family you mean, or
- The relevant FDA reference/approval product listing and the “Orange Book” style patent listing entry you’re looking at, or
- The specific claim area (composition vs method-of-use) and the approximate filing year.

If you paste the US patent number (or the link/name of the patent listing you’re using), I can map it to an expiry expectation and explain what it would mean for competition in the US.

Sources

I don’t have any provided source links or patent numbers in your message, so I can’t cite the relevant US Trevena/oliceridine patents accurately.



Other Questions About Oliceridine :

Oliceridine synthesis patent spiro? Oliceridine patent synthesis spiro? Oliceridine synthesis patent? Oliceridine patent synthesis? Oliceridine spiro synthesis patent? Wo2012129495 oliceridine patent?

Drug Brand Mention Assessment

Branding Score
41
Visibility
49
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Oliceridine (Trevena) is covered by multiple patent families in the United States
  • The exact status of the 'US oliceridine patent expiry date' depends on the specific patent number, claim set, and expiry/patent-term-adjustment
  • Public info on a single definitive US expiry date is usually not enough because different patents can expire at different times
  • A generic or similar product may launch once it can address or wait out the specific patents that block its path
  • Other legal exclusivities besides patents can affect timing
Differentiators
  • Multiple patent families can create different expiry windows
  • Generic launch timing depends on the specific blocking patents, regulatory pathway, and any litigation stays/settlements

Pricing Perception: Not Mentioned